New York, January 23, 2026, 05:29 EST — Premarket
- Shares of Novo Nordisk climbed almost 5% in premarket trading following fresh data showing a steep rise in prescriptions for the Wegovy pill
- Analysts see early prescription runs as an initial gauge of whether the oral drug can expand demand in the U.S.
- Attention now turns to Novo’s Feb. 4 results, crucial for clues on 2026 targets and how quickly the rollout will progress
Novo Nordisk A/S (NVO) shares jumped 4.9% to $62.23 in premarket trading Friday following new data revealing a strong surge in U.S. prescriptions for its Wegovy weight-loss drug. The stock closed Thursday at $59.32.
The numbers matter because investors now use weekly prescription data as a near-real-time indicator of demand for new obesity drugs, well ahead of quarterly sales reports.
Novo is fighting to hold its ground in the GLP-1 drug space — medications that suppress appetite and regulate blood sugar — as competitors ramp up their efforts. The market, meanwhile, has already made up its mind ahead of the earnings report.
Symphony Health data revealed weekly prescriptions for Wegovy’s oral form surged to 20,392 from just 4,286, while the once-weekly injection prescriptions remained flat. Bank of America analysts estimate that around 2,000 weekly prescriptions are needed to hit 2026 sales targets. Berenberg highlighted growing U.S. search interest, telehealth partnerships, and a revamped NovoCare pharmacy as signs of a “clear intention to embrace the consumer opportunity in obesity.” Novo’s shares, listed in Copenhagen, climbed 3% early Friday but remain down 34% over the past year, according to the report. (MarketWatch)
Sesame, a cash-pay healthcare platform, announced a partnership with Novo as a NovoCare “Recognized Care Provider” to expand access to the Wegovy pill across the U.S. Dave Moore, Novo’s executive VP for U.S. operations, described it as “a simple, direct-to-patient path to care.” Sesame CEO David Goldhill emphasized the goal is to present pricing “at a price they understand” before patients even book appointments. The platform lists medication costs starting at $149 a month for self-pay patients, dropping to as low as $25 a month for those with commercial insurance. (Business Wire)
Shares of rival Eli Lilly climbed 0.8% in premarket action. For many investors, the two stocks have been closely linked, with sentiment shifting over which company seems better positioned to grow the market beyond just injections.
Patent cliffs and lower-cost generics continue to shadow semaglutide, the key ingredient in Wegovy and Ozempic. India’s Sun Pharmaceutical recently got the green light to produce and market generic semaglutide, aiming for a launch once the patent expires in March. Vishal Manchanda, an analyst at Systematix Institutional Equities, noted that “generic players will come in with lower prices.” (Reuters)
New data this week added fuel to the debate over how long patients remain on GLP-1 therapy. An analysis of real-world evidence, shared with Reuters, indicated that many patients maintained weight loss even after stopping GLP-1 drugs. Venky Soundararajan, chief scientific officer at nference, said “durability is achievable in routine care.” Still, researchers cautioned about the limitations inherent in observational studies. (Reuters)
For Novo Nordisk stock, the real question now is if prescription growth sticks after the initial excitement dies down and access expands. Weekly trackers can swing wildly, yet they’ve turned into a crucial indicator for traders.
Novo’s fourth-quarter results drop on Feb. 4, ahead of the NASDAQ Copenhagen open, with an earnings call scheduled later the same day. Investors will zero in on 2026 guidance and updates on the rollout speed of the Wegovy pill. (Novonordisk)
